Novartis AG stock (CH0012005267): Cosentyx PMR data spotlighted as shares consolidate after Q1 strength

Novartis AG shares were little changed on SIX Swiss Exchange on 06/03/2026 as investors weighed fresh Phase III Cosentyx data in polymyalgia rheumatica against the strong Q1 2026 performance already priced into the Swiss pharma heavyweight.

Novartis AG shares traded broadly steady on SIX Swiss Exchange on 06/03/2026, after a modestly softer close on 06/02/2026, as the Swiss blue chip drew attention with new Phase III data for its immunology drug Cosentyx in polymyalgia rheumatica (PMR) while investors continued to digest solid Q1 2026 results, according to Reuters as of 06/03/2026 and company disclosures as of 04/23/2026.

According to the company, Cosentyx (secukinumab) achieved a statistically significant and clinically meaningful improvement in sustained remission compared with placebo through week 52 in PMR patients in the Phase III REPLENISH trial, with twice as many patients on Cosentyx reaching sustained remission, based on a Novartis media release dated 06/03/2026 and aligned coverage on MarketScreener as of 06/03/2026.

Novartis stated that the REPLENISH data, published in the New England Journal of Medicine and presented at the 2026 EULAR Congress on 06/03/2026, also showed a significant steroid-sparing effect over 52 weeks, underscoring the potential of Cosentyx in an indication that currently relies heavily on long-term glucocorticoid therapy, according to the same Novartis 06/03/2026 release and supplemental summaries by MarketScreener as of 06/03/2026.

The stock traded at around CHF 95 on SIX Swiss Exchange under the ticker NOVN on 06/03/2026, compared with a previous close near CHF 94.50 on 06/02/2026, according to SIX price data and Morningstar quote information as of 06/03/2026, while the US-listed American depositary shares on the New York Stock Exchange under ticker NVS changed hands near USD 168.60 after a prior close of USD 165.51, as per Morningstar data as of 06/03/2026.

In Germany, Novartis shares were also available via Tradegate and Frankfurt in euros, with indicative pricing close to the Swiss franc value adjusted for FX on 06/03/2026, according to German trading-venue snapshots as of that date, offering an additional access point for investors in the DACH region.

Novartis, headquartered in Basel, Switzerland, reiterated on 04/23/2026 its full-year 2026 guidance after reporting Q1 2026 net sales and core operating income that declined in constant currencies compared with the prior year, but the company emphasized ongoing portfolio focus and cost discipline, based on the Q1 2026 results release on the Novartis investor relations site dated 04/23/2026 and Morningstar commentary as of 04/23/2026.

Management has continued to position Novartis as a focused innovative medicines player following recent portfolio streamlining moves, including the separation of its generics unit Sandoz completed in 2023, according to company background from Novartis annual reporting and investor materials as of 2024, meaning that potential new indications such as PMR for Cosentyx could directly support its higher-margin specialty medicines strategy.

As of: 06/03/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Novartis
• Sector/industry: Pharmaceuticals and biotechnology (innovative medicines focus)
• Headquarters/country: Basel, Switzerland
• Core markets: Europe, United States, Japan and other international markets
• Key revenue drivers: Innovative prescription drugs across immunology, oncology, cardiovascular, neuroscience and ophthalmology, including key brands such as Cosentyx and Entresto, as outlined in Novartis annual reporting as of 2024
• Home exchange/listing venue: SIX Swiss Exchange (NOVN); secondary listing via NYSE ADRs (NVS)
• Trading currency: CHF for primary Swiss listing; USD for NYSE ADRs

Novartis AG: core business model

With its sharpened focus on innovative branded medicines following recent portfolio simplifications, Novartis concentrates on specialty therapeutics in areas such as immunology, oncology and cardiovascular disease, where the commercial performance of high-profile drugs like Cosentyx and Entresto plays a central role in driving its revenue mix and margin profile.

Novartis AG in peer comparison

Against other large-cap European pharma names, Novartis is often viewed alongside peers such as Roche and Sanofi, which also derive substantial revenues from innovative prescription drugs and biologics, according to company filings and investor materials from these groups as of 2024.

Roche, headquartered in Basel and listed on SIX, reported group sales of CHF 60.0 billion in 2023 with roughly two-thirds generated by its Pharmaceuticals division, as per the Roche 2023 annual report published in early 2024, while Sanofi, listed on Euronext Paris, posted 2023 net sales of EUR 43.1 billion with about 72 percent attributable to its Innovative Medicines segment, according to the Sanofi 2023 annual report dated 02/29/2024.

Compared with these peers, Novartis delivered 2023 net sales of USD 45.4 billion and core operating income of USD 16.5 billion, based on the Novartis 2023 annual report dated 01/31/2024, which places the Swiss company broadly in line with other European pharma majors by revenue scale while emphasizing a streamlined portfolio more heavily skewed toward higher-margin innovative therapies after the Sandoz spin-off in 2023.

In therapeutic focus, Cosentyx positions Novartis in the competitive immunology and inflammatory disease market where Roche has strengths in areas such as autoimmune disorders through products like Rituxan/MabThera and Ocrevus, while Sanofi is present in atopic and inflammatory conditions with drugs such as Dupixent, according to Roche and Sanofi product information and investor updates as of 2024, highlighting the crowded field into which any new PMR indication for Cosentyx would be introduced.

From a geographic exposure standpoint, all three companies derive meaningful portions of sales from the United States market in addition to Europe, with Novartis stating that the US represented roughly one-third of its 2023 net sales, Roche citing about 45 percent of group sales from North America and Sanofi noting that the United States is its single largest market by revenue, based on their 2023 annual reports, underscoring the importance of US pricing and access dynamics for specialty medicines in shaping the competitive landscape.

Conclusion

The 06/03/2026 Phase III REPLENISH results in polymyalgia rheumatica put Cosentyx at the center of the latest news flow around Novartis, even as the share price on SIX Swiss Exchange remained relatively steady following a prior day of slightly softer trading.

In the broader context of large European pharma peers like Roche and Sanofi, the data underline how Novartis is seeking to expand its immunology and inflammatory disease footprint through additional indications for key brands rather than through major portfolio diversification.

For investors tracking the Swiss group, the combination of Q1 2026 fundamentals, the ongoing rollout of new and expanded indications and the competitive positioning versus other global pharma majors will likely remain central reference points when assessing how developments such as the Cosentyx PMR data may influence the longer-term earnings profile.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.